Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Catumaxomab intraperitoneal infusion with versus without prednisolone premedication in malignant ascites
2008-001557-17Phase 4Completed
- Sponsor
- Fresenius
- Start
- Jul 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of catumaxomab and prednisolone in malignant ascites and Epithelial cancer is not a specific disease name; it is a broad category referring to cancers that arise from epithelial cells. The most common and clinically recognized example is "epithelial ovarian cancer". However, the term alone does not specify a single disease (2 arms), sponsored by Fresenius. Primary endpoints: Primary safety comparison and Primary efficacy comparison. Started Jul 2008; status: completed.
02
Drugs
catumaxomabprednisolone
03
Conditions
malignant ascitesEpithelial cancer is not a specific disease name; it is a broad category referring to cancers that arise from epithelial cells. The most common and clinically recognized example is "epithelial ovarian cancer". However, the term alone does not specify a single disease.
Beyond the preview
Go deeper on 2008-001557-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001557-17.